ISSN 1671-5411 CN 11-5329/R
Jing DAI, Shu-Zheng LYU, Yun-Dai CHEN, Xian-Tao SONG, Min ZHANG, Wei-Min LI, Yang ZHENG, Shang-Yu WEN, Shao-Ping NIE, Yu-Jie ZENG, Hai GAO, Yi-Tong MA, Shu-Yang ZHANG, Li-Jun GUO, Zheng ZHANG. Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction: a multicenter random-ized clinical trial. J Geriatr Cardiol 2017; 14(2): 108-117. doi: 10.11909/j.issn.1671-5411.2017.02.005
Citation: Jing DAI, Shu-Zheng LYU, Yun-Dai CHEN, Xian-Tao SONG, Min ZHANG, Wei-Min LI, Yang ZHENG, Shang-Yu WEN, Shao-Ping NIE, Yu-Jie ZENG, Hai GAO, Yi-Tong MA, Shu-Yang ZHANG, Li-Jun GUO, Zheng ZHANG. Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction: a multicenter random-ized clinical trial. J Geriatr Cardiol 2017; 14(2): 108-117. doi: 10.11909/j.issn.1671-5411.2017.02.005

Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction: a multicenter random-ized clinical trial

doi: 10.11909/j.issn.1671-5411.2017.02.005
Funds:

This study was supported by the Ministry of Science and Technology of the People’s Republic of China, State Science and Technology Support Program (No.2011BAI11B05). We thank all investigators and participants of this study for their valuable contributions. We appreciate the valuable help of Dr. Roberto Patarca for polish of the manuscript. The authors declare no commercial conflicts of interest.

  • Received Date: 2016-11-03
  • Rev Recd Date: 2017-02-06
  • Publish Date: 2017-02-28
  • Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction (STEMI) patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and results It was a prospective, multicenter, randomized controlled trial. Between April 2012 and July 2015, 399 acute STEMI patients with single vessel disease and intermediate (40%–70%) stenosis of the culprit lesion before or after aspiration thrombectomy and/or intracoronary tirofiban (15 μg/kg) were enrolled and were randomly assigned (1: 1) to stenting group (n = 201) and non-stenting group (n = 198). In stenting group, patients received pharmacologic therapy plus standard percutaneous coronary intervention (PCI) with stent implantation. In non-stenting group, patients received pharmacologic therapy and PCI (thrombectomy), but without dilatation or stenting. Primary endpoint was 12-month rate of major adverse cardiac and cerebrovascular events (MACCE), a composite of cardiac death, non-fatal myocardial infarction (MI), repeat revascularization and stroke. Secondary endpoints were 12-month rates of all cause death, ischemia driven admission and bleeding complication. Median follow-up time was 12.4 ± 3.1 months. At 12 months, MACCE occurred in 8.0% of the patients in stenting group, as compared with 15.2% in the non-stenting group (adjusted HR: 0.42, 95% CI: 0.19–0.89, P = 0.02). The stenting group had lower non-fatal MI rate than non-stenting group, (1.5% vs. 5.5%, P = 0.03). The two groups shared similar cardiac death, repeat revascularization, stroke, all cause death, ischemia driven readmission and bleeding rates at 12 months. Conclusions Stent implantation had better efficacy and safety in reducing MACCE risks among acute STEMI patients with single vessel intermediate stenosis culprit lesions.
  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (942) PDF downloads(896) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return